Does TRT Cause Prostate Cancer? The Complete Evidence-Based Answer (2026)

Does TRT Cause Prostate Cancer? The Complete Evidence-Based Answer (2026)

This is one of the most common questions asked about testosterone replacement therapy — and one of the most misunderstood. For decades, the medical community operated under the “androgen hypothesis”: the belief that testosterone fuels prostate cancer growth. This idea was so entrenched that men with a history of prostate cancer were permanently excluded from TRT. But the evidence has shifted dramatically. Here is what the research actually shows as of June 2026.

Where Did the “Testosterone Causes Prostate Cancer” Myth Come From?

The myth traces back to 1941, when Dr. Charles Huggins published a paper showing that reducing testosterone levels in men with advanced metastatic prostate cancer caused tumor regression. He won the Nobel Prize for this discovery in 1966. The logical leap that followed — “if lowering testosterone shrinks tumors, then testosterone must cause prostate cancer” — became medical dogma for 70+ years. This was the androgen hypothesis. It was taught in every medical school. It was wrong.

The Saturation Model: Why More Testosterone Doesn’t Mean More Cancer Risk

Prostate tissue responds to testosterone through androgen receptors, but these receptors become saturated at relatively low testosterone levels — around 200-250 ng/dL. Above this level, adding more testosterone produces no additional prostate stimulation. This is called the saturation model, and it explains why:

• Men with normal testosterone (300-1000 ng/dL) have no higher prostate cancer risk than men with low-normal testosterone
• Raising testosterone from low to normal does not increase prostate cancer risk
• The relationship between testosterone and prostate cancer is not linear — it plateaus once the saturation threshold is reached

The Evidence: What the Major Studies Show

Can Men With a History of Prostate Cancer Take TRT?

This is the most nuanced question in the field, and the answer has evolved significantly:

• Active prostate cancer: TRT is contraindicated. No responsible physician will prescribe testosterone to a man with untreated or active prostate cancer.
• Post-radical prostatectomy (surgery): A growing body of evidence suggests TRT may be safe in carefully selected men with undetectable PSA after surgery. A 2018 meta-analysis in Journal of Urology found no increase in biochemical recurrence in men receiving TRT after radical prostatectomy. This is an individualized decision requiring shared decision-making with a urologist.
• Post-radiation with undetectable PSA: Evidence is more limited but cautiously supportive. Most guidelines still recommend against routine TRT in this population, but case-by-case exceptions are sometimes made in major academic centers.
• Active surveillance (low-risk prostate cancer): TRT is not recommended. While the risk of progression is debated, the standard of care is to avoid TRT in men under active surveillance.

PSA Monitoring on TRT: What to Expect

All responsible TRT protocols include PSA monitoring. Here is what the data shows about PSA changes on TRT:

• PSA typically rises 0.3-0.5 ng/mL in the first 3-6 months of TRT as the prostate normalizes from a hypogonadal state
• This rise typically plateaus and does not continue to increase
• A PSA rise >1.0 ng/mL in the first year, or a continued rise beyond the first year, warrants urological evaluation
• PSA velocity (rate of change) is more informative than absolute PSA level
• At Viking Alternative Medicine, PSA is checked at baseline, 3 months, 6 months, and annually thereafter — with automatic physician review of any concerning trend

What Medical Societies Say (2024-2026 Guidelines)

Frequently Asked Questions

Does TRT increase PSA levels dangerously?

No. PSA typically rises 0.3-0.5 ng/mL and then stabilizes. A sustained rise >1.0 ng/mL in the first year warrants investigation, but this is uncommon in properly dosed TRT.

What if I have a family history of prostate cancer?

A family history of prostate cancer is not a contraindication to TRT, but it warrants more frequent PSA monitoring (every 6 months instead of annually) and a lower threshold for urological referral if PSA rises. The saturation model still applies — TRT does not increase prostate cancer risk even in higher-risk populations.

Does TRT cause BPH (enlarged prostate)?

No. Clinical trials consistently show no increase in prostate volume or urinary symptoms with TRT compared to placebo. The prostate is an androgen-sensitive organ, but like prostate cancer risk, the effect plateaus at the saturation threshold.

Can TRT make an existing undiagnosed prostate cancer grow faster?

This is the theoretical concern that drives screening requirements. However, the TRAVERSE trial — which monitored PSA in all 5,246 men — found no evidence that TRT unmasked or accelerated subclinical prostate cancer. The saturation model provides the mechanistic explanation: once androgen receptors are saturated at ~250 ng/dL, more testosterone does not produce more prostate stimulation.

How does Viking Alternative Medicine screen for prostate cancer before TRT?

Every Viking patient — under the medical oversight of Dr. Ana Lisa Carr, MD — receives a baseline PSA, comprehensive metabolic panel, and complete blood count. PSA levels are monitored at 3 months, 6 months, and annually thereafter. Any concerning trend triggers an automatic physician review and, if indicated, a urology referral. Viking physicians follow AUA and Endocrine Society guidelines for prostate safety monitoring.

Last updated: June 10, 2026. References: TRAVERSE trial (Lincoff et al., NEJM 2023); Endogenous Hormones and Prostate Cancer Collaborative Group (JNCI 2008); Cui et al. meta-analysis (Urology 2014); AUA Testosterone Deficiency Guideline 2024; Endocrine Society Clinical Practice Guideline 2024; European Urology Focus meta-analysis (2021).